Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Marvell in conjunction with the acquisition of Xelerated
Mandate

Vinge advises Marvell in conjunction with the acquisition of Xelerated

January 11, 2012

Vinge has advised Marvell Semiconductors Inc., the world leader within semiconductor solutions and quoted on NASDAQ in conjunction with the acquisition of Xelerated, which provides technology solutions for industrial networks. Xelerated’s majority owner is the Sixth AP fund.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Paul Dali and Albert Wållgren. Partner Fredrik Dahl and associate Åsa Gotthardsson provided advice on the employment law aspects of the transaction and partner Mattias Schömer and associate Tora Hansjons provided tax law advice.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026